Kintara Therapeutics Inc KTRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KTRA is a good fit for your portfolio.
News
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, CTLT, SCX, KTRA
-
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRA
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, SCX, KTRA
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, KTRA, ABIO
-
KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA
-
Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm
-
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIK, CHX, KTRA, ABIO
-
Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURA
Trading Information
- Previous Close Price
- $0.14
- Day Range
- $0.13–0.16
- 52-Week Range
- $0.08–5.98
- Bid/Ask
- $0.16 / $0.16
- Market Cap
- $6.17 Mil
- Volume/Avg
- 11.2 Mil / 14.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 2
- Website
- https://www.kintara.com
Valuation
|
Metric
|
KTRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
KTRA
Financial Strength
|
Metric
|
KTRA
|
|---|---|
Quick Ratio | 0.57 |
Current Ratio | 0.63 |
Interest Coverage | — |
Quick Ratio
KTRA
Profitability
|
Metric
|
KTRA
|
|---|---|
Return on Assets (Normalized) | −202.58% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −547.90% |
Return on Assets
KTRA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tsptxhbzk | Jfv | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dfzkcsgpl | Kbmkmx | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bsmhzhlm | Tvhzyy | $99.5 Bil | |
MRNA
| Moderna Inc | Mzrzgpsyv | Pcmr | $38.8 Bil | |
ARGX
| argenx SE ADR | Wqrtlnw | Vttx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Jjxsfsvg | Kvlm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mltxqcfny | Jdfhjt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wprddqk | Lgfbgb | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Psvwcbbm | Fqsmbtr | $12.5 Bil | |
INCY
| Incyte Corp | Nyxvslrn | Yjjmvfq | $11.6 Bil |